Skip to main
LYEL

Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma (LYEL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lyell Immunopharma is an innovative company with a promising pipeline of next-generation CAR-T therapies for hematologic malignancies and solid tumors, with rondecabtagene autoleucel and their novel GCC-targeted CAR-T product showing potential for improved efficacy and safety.However, they may face challenges with obtaining regulatory approval and competition in the market. With a strong technology and manufacturing process, the company has potential for long-term success in the cell therapy market.

Bears say

Lyell Immunopharma is at risk of facing lower than expected payer reimbursement due to high costs and potential production limitations for their CAR-T therapeutics, impacting their market potential. Additionally, concerns have been raised regarding the durability and persistence of their lead CAR-T candidate, rondecabtagene autoleucel, compared to other CAR-T products on the market. Key questions remain around the strength of correlations between ronde-cel's product composition and clinical durability, specifically in the PiNACLE study and when compared to other CD19/CD20 CAR-Ts.

Lyell Immunopharma (LYEL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lyell Immunopharma (LYEL) Forecast

Analysts have given Lyell Immunopharma (LYEL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lyell Immunopharma (LYEL) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lyell Immunopharma (LYEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.